Abiraterone or darolutamide for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study is comparing two drugs, abiraterone and darolutamide, to see how well they work for advanced prostate cancer. You might join if your cancer has spread and your doctor agrees these treatments could help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that has spread or is advanced.
- You are willing to take either abiraterone with prednisone or darolutamide.
- You are currently on hormone therapy or had surgery to remove the testicles.
- You are 18 years or older.
- You are able to go to study visits and follow the study plan.
- You have not taken abiraterone or darolutamide for more than 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for men with advanced prostate cancer that has stopped responding to usual hormone therapy. It compares high-dose testosterone followed by darolutamide to standard care, and may help control the cancer longer.
This study tests a new form of abiraterone (a hormone therapy) against the standard one in men whose prostate cancer has spread and no longer responds to usual hormone treatment. Participants must have had limited prior treatments and be in decent overall health.
This trial tests adding abiraterone (a hormone therapy pill) and prednisone to standard hormone therapy (ADT) for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. The goal is to see if this combination works better than ADT alone.
This study looks at how the immune system reacts to advanced prostate cancer that has spread to other parts of the body. Researchers will use special techniques to analyze tissue samples, hoping to find new ways to treat this cancer.
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
This trial compares a personalized (adaptive) treatment plan versus a steady (continuous) plan using either abiraterone or enzalutamide (with the same standard hormone-suppression). It aims to see which approach controls advanced metastatic prostate cancer better while keeping side effects manageable.
Hear when a new Stage III Prostate Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.